LumaCina appoints Gary Bird as CEO as Mark Crotty remains executive chair

The Bridgewest Group portfolio company said Bird brings more than three decades of Australian pharmaceutical leadership experience as LumaCina expands its sterile injectable medicines business in Australia and overseas.

Summary

verifying reliability

Terms & Concepts

No specialized terms available for this topic.